Huminsulin Basal (Nph) (Insulin Human (Rdna))

Huminsulin Basal (NPH) is indicated for the long‑acting insulin needs of patients with diabetes.

• Initiation of basal insulin therapy in adults with type 1 diabetes mellitus.
• Supplementing basal insulin requirements in type 2 diabetes when oral agents are insufficient.
• Adjusting background insulin in patients transitioning from multiple daily injections to a simplified regimen.
• Providing once‑ or twice‑daily dosing to maintain stable fasting glucose levels.
• Use as part of a comprehensive diabetes management plan that includes diet, exercise, and glucose monitoring.

• Huminsulin Basal contains recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑K/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell surface, increasing glucose uptake, and suppressing hepatic gluconeogenesis. The NPH formulation prolongs absorption, providing a relatively steady insulin level over 12–18 hours during the dosing interval.

Adverse reactions to Huminsulin Basal can vary in frequency and severity.

Common

• Mild hypoglycemia, often occurring when meals are delayed, carbohydrate intake is insufficient, or physical activity is increased.
• Injection site reactions such as redness, swelling, itching, or a transient lump that usually resolve without intervention.
• Lipodystrophy presenting as localized thickening (lipohypertrophy) or loss of subcutaneous fat (lipoatrophy) at repeated injection sites.
• Transient weight gain related to improved glycemic control and fluid balance, typically modest in magnitude.

Serious

• Severe hypoglycemia with neuroglycopenic symptoms such as confusion, seizures, or loss of consciousness, requiring immediate treatment.
• Allergic reactions ranging from urticaria and angio‑edema to life‑threatening anaphylaxis.
• Edema or fluid retention leading to peripheral swelling, which may be exacerbated by high sodium intake or heart failure.
• Rare cases of insulin‑induced hypokalemia, especially in patients receiving high doses or concomitant diuretics.

When prescribing or using Huminsulin Basal, several precautions should be considered to minimize risks and ensure safe therapy.

• Assess renal and hepatic function, as impairment may alter insulin clearance.
• Review patient’s history of hypoglycemia unawareness before initiating therapy.
• Adjust doses during periods of illness, reduced food intake, or increased physical activity.
• Avoid using the same injection site repeatedly to reduce the risk of lipodystrophy.
• Monitor weight, blood pressure, and signs of fluid retention, especially in patients with cardiac disease.
• Counsel pregnant or breastfeeding women that safety data are limited and treatment decisions should be individualized.

Huminsulin Basal may interact with other medicines or substances that affect glucose metabolism or insulin action.

Avoid

• Concurrent use of other rapid‑acting insulins or insulin analogues without proper dose adjustment, which can cause severe hypoglycemia.
• Co‑administration with meglitinides (e.g., repaglinide, nateglinide) that also stimulate insulin release, increasing hypoglycemia risk.

Use with caution

• Beta‑blockers, which may mask hypoglycemia symptoms and prolong its duration.
• Corticosteroids, thiazide diuretics, or atypical antipsychotics that can raise blood glucose and require higher insulin doses.
• Alcohol consumption, especially in excess, which can cause unpredictable glucose fluctuations and delayed hypoglycemia.
• Oral hypoglycemic agents such as sulfonylureas may potentiate insulin effect and increase hypoglycemia risk.